Sign in

You're signed outSign in or to get full access.

EB

Ensysce Biosciences, Inc. (ENSC)·Q3 2025 Earnings Summary

Executive Summary

  • Q3 2025 reported federal grant revenue of $0.49M and EPS of -$1.29; both missed S&P Global consensus (revenue $1.40M*, EPS -$0.76*) as grant timing drove a sharp YoY decline and wider loss. Actual: revenue $0.49M ; EPS -$1.29 . Consensus: revenue $1.40M*; EPS -$0.76*.
  • Strategic progress: PF614 Phase 3 (PF614-301) initiated in July and collaboration with Rho, Inc., marking a pivotal step toward potential approval .
  • Regulatory momentum: FDA provided encouraging feedback on PF614-MPAR, supporting overdose protection labeling and a potential streamlined 505(b)(2) pathway; PF614-MPAR holds Breakthrough Therapy designation .
  • Liquidity: Cash was $1.67M at quarter-end; a subsequent $4.0M Series B convertible preferred offering closed with up to $16.0M additional tranches available over 24 months, bolstering funding capacity .
  • Stock catalysts: execution on PF614 Phase 3 (data flow, enrollment updates), FDA interactions on overdose labeling/505(b)(2), and staged financing drawdowns are likely to drive narrative and trading reaction .

What Went Well and What Went Wrong

What Went Well

  • Initiated pivotal Phase 3 PF614-301 study (post‑abdominoplasty pain), a key de‑risking milestone ahead of potential regulatory filing; CRO partnership with Rho aims to ensure rigorous execution . Quote: “The initiation of our pivotal Phase 3 PF614-301 trial in July marks a major milestone in our mission to transform pain management.” — Dr. Lynn Kirkpatrick .
  • Regulatory traction: FDA feedback supports overdose protection labeling for PF614‑MPAR and a streamlined 505(b)(2) path, potentially expediting market entry . Quote: “The FDA supported Ensysce’s pursuit of overdose protection labeling and confirmed the potential for a streamlined 505(b)(2) regulatory pathway…” .
  • Financing secured: $4.0M initial preferred stock proceeds and the ability to access up to $16.0M via future tranches over 24 months strengthens liquidity to fund clinical programs .

What Went Wrong

  • Top‑line underperformed: Federal grants revenue fell to $0.49M from $3.42M YoY, reflecting grant timing and lower reimbursable activity; revenue missed consensus $1.40M* . Consensus: $1.40M*.
  • Operating spend rose: R&D increased to $2.95M vs. $1.69M YoY driven by PF614/PF614‑MPAR clinical activity, widening operating loss to -$3.74M vs. +$0.64M YoY (boosted by prior grant timing) .
  • EPS missed: -$1.29 vs. -$0.76* consensus, as higher R&D coupled with weaker grant recognition overshadowed modest other income . Consensus: -$0.76*.

Financial Results

Core P&L vs. Prior Quarters

MetricQ1 2025Q2 2025Q3 2025
Federal Grants Revenue ($USD)$1.32M $1.37M $0.49M
Total Operating Expenses ($USD)$3.29M $3.12M $4.23M
Income (Loss) from Operations ($USD)-$1.97M -$1.75M -$3.74M
Net Income (Loss) per Share (Basic & Diluted) ($)-$1.39 -$0.79 -$1.29

Q3 Actuals vs. S&P Global Consensus

MetricActualConsensusSurprise
Revenue ($USD)$493,104 $1,398,870*-$905,766
EPS ($)-$1.29 -$0.76*-$0.53

Values with asterisk (*) retrieved from S&P Global.

Year-over-Year (Q3 2025 vs. Q3 2024)

MetricQ3 2024Q3 2025
Federal Grants Revenue ($USD)$3,418,853 $493,104
R&D Expense ($USD)$1,690,674 $2,954,909
G&A Expense ($USD)$1,083,433 $1,279,290
Net Income (Loss) ($USD)$661,769 -$3,729,128
EPS (Basic & Diluted) ($)$1.00 -$1.29

KPIs and Liquidity

MetricQ1 2025Q2 2025Q3 2025
R&D Expense ($USD)$1,885,528 $1,923,430 $2,954,909
G&A Expense ($USD)$1,401,756 $1,198,523 $1,279,290
Cash & Equivalents ($USD, period-end)$3,052,491 $2,211,575 $1,673,218
Cash from Ops (YTD) ($USD)-$1,707,412 -$4,414,280 -$6,280,459

Segment breakdown: Not applicable; the company reports as a single operating entity with grant revenue and R&D/G&A .

Non-GAAP: No non-GAAP adjustments disclosed in Q3 materials .

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
Revenue/Expense GuidanceFY/Q4 2025Not providedNot providedMaintained (no guidance)
Regulatory Path (PF614‑MPAR)OngoingBreakthrough Therapy designation; ongoing FDA dialogueFDA feedback supports overdose protection labeling and potential 505(b)(2) pathwayRaised confidence in pathway
Financing CapacityNext 24 monthsNot applicable$4.0M initial; up to $20.0M total ($4.0M initial + $16.0M subsequent tranches)New financing framework

Dividend, OI&E, tax rate, and segment guidance: Not provided .

Earnings Call Themes & Trends

Note: A Q3 2025 earnings call transcript was not found in the document catalog; press releases are used to track themes [ListDocuments returned none].

TopicPrevious Mentions (Q1 2025)Previous Mentions (Q2 2025)Current Period (Q3 2025)Trend
PF614 Phase 3 (abdominoplasty pain)Preparing design; initiation targeted mid-year 2025 Announced initiation of PF614-301; engaged Rho Reinforced July initiation; execution focus Advancing execution
PF614‑MPAR overdose protectionPF614‑MPAR‑102 Part 1 completed; overdose protection confirmed PF614‑MPAR‑102 Part 2 fully enrolled; ongoing Part 3 FDA feedback supports overdose labeling; potential 505(b)(2) Regulatory pathway de‑risking
OUD program (PF9001)Patent Notice of Allowance; safer methadone analogue vision Notice of Allowance; IP strengthening Progressing toward non-clinical studies; HEAL grant support Continued build-out
NIDA/Federal grantsIncreased activity under MPAR grant; timing-driven Received $5.3M installment; reimbursement through May 2026 Q3 grants lower on timing; MPAR/OUD cadence explained Variable timing
Financing/liquidityWarrants exercised post‑Q1 Cash $2.21M at Q2; YTD financing inflow $4.0M initial Series B preferred; up to $16.0M additional Strengthened runway

Management Commentary

  • “The initiation of our pivotal Phase 3 PF614-301 trial in July marks a major milestone in our mission to transform pain management.” — Dr. Lynn Kirkpatrick, CEO .
  • “We are also buoyed by encouragement from the FDA for our PF614-MPAR program, with Breakthrough Therapy designation, including working to align on overdose protection labeling and a regulatory pathway forward.” .
  • “Our current investors have continued to support this development path through a convertible preferred stock financing… with potentially $16 million of additional funding available through future tranches over the next 24 months.” .

Q&A Highlights

  • A Q3 2025 earnings call transcript was not available in the document catalog; no call Q&A themes could be extracted. We searched and found no transcript to read via ListDocuments [ListDocuments returned none].

Estimates Context

  • EPS: -$1.29 vs. -$0.76* consensus; miss driven by higher R&D and lower grant recognition in the period . Consensus: -$0.76*.
  • Revenue: $0.49M vs. $1.40M* consensus; miss primarily due to grant timing under MPAR/OUD programs . Consensus: $1.40M*.
  • Coverage depth: Only one estimate on both EPS and revenue (Primary EPS - # of Estimates = 1; Revenue - # of Estimates = 1)*.

Values with asterisk (*) retrieved from S&P Global.

Key Takeaways for Investors

  • Near-term trading likely tied to PF614 Phase 3 operational updates (enrollment cadence, interim safety) and any 505(b)(2) regulatory clarity for PF614‑MPAR; these could re‑rate regulatory probability of success .
  • Liquidity improved: $1.67M cash at Q3 plus $4.0M closed and up to $16.0M additional preferred tranches provides optionality; watch shareholder approval and issuance caps in financing documents for potential dilution dynamics .
  • Top-line is grant-timing driven; Q3 revenue volatility underscores the need to focus on clinical/regulatory milestones rather than quarterly grant recognition for valuation .
  • Spend trend: R&D stepped up materially in Q3 with Phase 3 ramp; expect continued operating losses as trials progress, consistent with clinical-stage profile .
  • Regulatory momentum for overdose protection labeling and potential 505(b)(2) could shorten timelines; monitoring FDA interactions and labeling outcomes is critical for MPAR’s commercial narrative .
  • Financing terms include conversion mechanics, exchange caps, and listing requirements; investors should track subsequent closings and share authorization increases, as these affect dilution and runway .
  • No quantitative guidance provided; expectations should anchor on milestones (PF614 data, MPAR food‑effect/Part 3 completion, IND trajectory for PF9001) rather than quarterly financial targets .

Sources: Q3 2025 8‑K 2.02 press release and exhibits ; Q2 2025 8‑K 2.02 ; Q1 2025 8‑K 2.02 ; Financing 8‑K and exhibits –. Additional press release replication: BioSpace coverage of Q3 results .